Study of Bee Venom Allergy Treatment and Risk Factors for Therapy Failure Using Bee Venom Immunotherapy in Adults Aged 18 to 70

What this Trial Is About

Researchers are studying bee venom allergy and the effectiveness of venom immunotherapy VIT, which is known to provide long-term protection from severe allergic reactions to insect stings. The study focuses on understanding why VIT is less effective for bee venom compared to vespid venom. They are particularly investigating whether sensitization to specific bee venom components, especially Api m 10, increases the risk of treatment failure. Participants will receive bee venom immunotherapy following protocols they can select. Before starting treatment, blood samples will be taken to measure specific IgE levels to bee venom components. After reaching maintenance doses, patients will undergo sting challenges to assess the treatment outcome and identify risk factors for failure related to sensitization and other factors like antibody levels and medication use. During the study, researchers will monitor participants through blood tests and controlled sting challenges, observing immune responses and any side effects. The primary outcome is to determine if predominant sensitization to Api m 10 predicts treatment failure within about six months after maintenance dose. Secondary outcomes include assessing other venom components, antibody levels, systemic side effects, and medication impact, with the total observation period depending on the timing of the sting challenge.

Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure